-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40

Benzinga·05/07/2026 12:57:29
Listen to the news
Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and raises the price target from $34 to $40.